FDA To Centocor: Show Me The REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.
You may also be interested in...
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
Stelara Clears FDA; Different Mechanism of Action, But REMS Looks Similar To TNF Class
Centocor's newest anti-inflammatory biologic - ustekinumab - actually has a different mechanism than the TNF inhibitors, but FDA has the sponsor using a risk management program similar to existing TNF drugs.